LUNG (Pulmonx) Ending Cash Position: $56.10 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LUNG Pulmonx Corp LUNG
57 GF Score
Price $2.44
GF Value $6.46
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is Pulmonx Ending Cash Position?

Pulmonx LUNG +12.04% 57 Ending Cash Position is $56.10 Mil as of Jun. 2026. GuruFocus rates LUNG with a GF Score™ of 57/100 and a GF Value™ of $6.46 (Possible Value Trap). The stock has 8 warning signs investors should review.

Pulmonx's Ending Cash Position for the quarter that ended in Jun. 2026 was $56.10 Mil.

Pulmonx's quarterly Ending Cash Position declined from Dec. 2025 ($70.01 Mil) to Mar. 2026 ($61.83 Mil) and declined from Mar. 2026 ($61.83 Mil) to Jun. 2026 ($56.10 Mil).

Pulmonx's annual Ending Cash Position declined from Dec. 2023 ($83.78 Mil) to Dec. 2024 ($71.16 Mil) and declined from Dec. 2024 ($71.16 Mil) to Dec. 2025 ($70.01 Mil).

Pulmonx Ending Cash Position Related Terms

Pulmonx Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Pulmonx's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pulmonx Ending Cash Position Chart

Pulmonx Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial 148.71 101.97 83.78 71.16 70.01

Pulmonx Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 75.73 76.81 70.01 61.83 56.10
LUNG
57GF Score
Pulmonx Corp LUNG
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pulmonx Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Pulmonx's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=71.162+-1.153
=70.01

Pulmonx's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=61.829+-5.727
=56.10

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $56.10 Mil mean?
Pulmonx (LUNG) has a Ending Cash Position of $56.10 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Pulmonx and its competitors.
Is Pulmonx's Ending Cash Position too high?
Pulmonx's current Ending Cash Position is $56.10 Mil. Overall, Pulmonx has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pulmonx's Ending Cash Position compare to SRTS and SNWV?
Pulmonx's Ending Cash Position of $56.10 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Devices & Instruments company?
A good Ending Cash Position depends on the Medical Devices & Instruments industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Pulmonx and its competitors. Pulmonx's current Ending Cash Position is $56.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pulmonx stock overvalued right now?
Based on GuruFocus' analysis, Pulmonx (LUNG) is currently considered Possible Value Trap. The stock's GF Value™ is $6.46, compared to a current price of $2.44 — trading 62.3% below its estimated fair value. The current Ending Cash Position is $56.10 Mil. Pulmonx's overall GF Score™ is 57/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Pulmonx (LUNG), the current Ending Cash Position is $56.10 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pulmonx (LUNG) Overvalued in 2026?

Based on GuruFocus' analysis, Pulmonx stock appears to be undervalued. The current stock price of $2.44 is trading 62.3% below its estimated GF Value™ of $6.46. GuruFocus considers Pulmonx to be Possible Value Trap.

Key valuation signals for LUNG:

  • Ending Cash Position: $56.10 Mil
  • GF Value™: $6.46 vs. price of $2.44 (62.3% below fair value)
  • GF Score™: 57/100 with 8 warning signs

No single metric tells the full story. See the LUNG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pulmonx Business Description

Other Exchanges 4NI:Germany
Address 700 Chesapeake Drive, Redwood, CA, USA, 94063
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.
57GF Score

Get the complete analysis for LUNG

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.44
Price
$6.46
GF Value